Highly Effective, Low-Intensity Therapy for Burkitt Lymphoma

News   Nov 14, 2013

 
Highly Effective, Low-Intensity Therapy for Burkitt Lymphoma
 
 
 

RELATED ARTICLES

Glythera Appoints Chief Scientific Officer and Strengthens SAB

News

Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.

READ MORE

New Treatment Target for Melanoma

News

Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma.

READ MORE

Missing Hormone Gene Linked to Incurable Prostate Cancer

News

A study has shown that the loss of a subtype of the gene HSD17B4 can contribute to treatment-resistant prostate cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE